Survival of the hospitalized patients with COVID‐19 receiving atorvastatin: A randomized clinical trial
- 22 March 2022
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (7) , 3160-3168
Abstract
As statins decrease the progression of sepsis and its related mortality, this study aimed to evaluate the effect of atorvastatin on survival and symptom improvement in hospitalized patients with COVID‐19. This randomized controlled trial was performed on 156 hospitalized patients with COVID‐19 in Bojnourd city in 2021. Patients were randomly divided into comparison (standard therapy: hydroxychloroquine + Kaletra®) and intervention groups (atorvastatin 20 mg, SD, plus standard therapy). The main outcomes were the rate of symptom improvement, duration of hospitalization, need for intubation, and mortality rate. In this study, seven patients died, two patients (2.6%) in the comparison group and five (6.6%) in the intervention group. The mean hospitalization days (p = 0.001), the pulse rate (p = 0.004), and the frequency of hospitalization in the ICU ward (18.4% vs. 1.3%) were longer and greater in the intervention group. The remission probability in the comparison group was greater (p = 0.0001). The median hospitalization days in the intervention group was longer (p < 0.001) and remission in the comparison group occurred 1.71 times sooner (hazard ratio = 1.70, 95% confidence interval = 1.22–2.38, p = 0.002). Totally, adding atorvastatin to the standard regime in this study increased hospitalization days and imposed negative effects on symptom improvement in hospitalized patients with COVID‐19.Keywords
This publication has 39 references indexed in Scilit:
- Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21AIDS, 2016
- Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modificationsBiochemical Pharmacology, 2015
- Imbalance Between Pulmonary Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Activity in Acute Respiratory Distress SyndromePediatric Critical Care Medicine, 2013
- Ambivalent Effects of Atorvastatin on Angiogenesis, Epidermal Cell Proliferation and Tumorgenesis in Animal Models2012
- Host Defense against Viral Infection Involves Interferon Mediated Down-Regulation of Sterol BiosynthesisPLOS Biology, 2011
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Recent advances in the angiotensin‐converting enzyme 2–angiotensin(1–7)–Mas axisExperimental Physiology, 2008
- Statin Adverse EffectsAmerican Journal of Cardiovascular Drugs, 2008
- Rapid immunomodulation by rosuvastatin in patients with acute coronary syndromeEuropean Heart Journal, 2006
- Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In Vivo and In VitroAntimicrobial Agents and Chemotherapy, 2001